Skip to main content

Advertisement

Table 2 Baseline demographics and disease characteristics for patients with vasodilatory shock

From: Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock

 Baseline angiotensin I/II ratioP value
<1.63 (n = 141)≥1.63 (n = 140)
Age, years
 Median (IQR)65 (51–76)63 (53–75)0.522
Sex (male/female), %58.9%/41.1%61.4%/38.6%0.715
Baseline MAP, mmHg
 Median (IQR)66.3 (63.3–68.7)67 (63.7–68.7)0.891
APACHE II
 Median (IQR)27 (22–33)29 (23–34)0.112
Albumin (g/dL)
 Median (IQR)2.2 (1.7–2.7)2.4 (2.0–2.8)0.007
SCVO2, %
 Median (IQR)77 (73.0–83.0)76.5 (72.2–82.0)0.211
Central venous pressure (mmHg)
 Median (IQR)12 (10–15)12 (10–16)0.317
Cardiac index
 Median (IQR)3.1 (2.6–4.0)3.1 (2.8–3.7)0.796
MELD score
 Median (IQR)22 (15–25)23 (17–28)0.046
Chest X-ray finding of ARDS, n (%)44 (31.2%)33 (23.7%)0.182
Medical history of ARDS, n (%)33 (23.4%)15 (10.7%)0.007
Exposure to ACE inhibitors, n (%)1 (0.7%)27 (19.3%)< 0.001
Exposure to ARBs, n (%)13 (9.2%)7 (5.0%)0.246
AKI with dialysis/CRRT, n (%)39 (27.7%)52 (37.1%)0.098
Vasopressin use during 6 h before randomization, n (%)93 (66.0%)102 (72.9%)0.244
Baseline norepinephrine-equivalent dose (μg/kg/min)
 Median (IQR)0.30 (0.22–0.49)0.39 (0.24–0.59)0.006
Median (IQR) ANG I level, (pg/mL)134 (42.7–468)354.5 (129–869.5)< 0.001
Median (IQR) ANG II level, (pg/mL)164 (45–552)42.35 (11.5–134.5)< 0.001
Median ANG I/II ratio (IQR)0.98 (0.67–1.21)5.36 (2.64–14.73)< 0.001
  1. ACE angiotensin-converting enzyme, AKI acute kidney injury, ANG angiotensin, APACHE II Acute Physiology and Chronic Health Evaluation II, ARB angiotensin II receptor type I blocker, ARDS acute respiratory distress syndrome, CRRT continuous renal replacement therapy, IQR interquartile range, MAP mean arterial pressure, MELD model for end-stage liver disease, SCVO2 central venous oxygen saturation